Aeromics

Aeromics is pioneering a novel approach to treating cerebral edema by inhibiting aquaporin-4 water channels, based on foundational research recognized by the Nobel Prize. Its lead program, AER-271, is in Phase 1 development for severe acute ischemic stroke, with a planned Phase 2 trial targeting patients with Large Hemispheric Infarction. The company is privately held, backed by venture capital and NIH grants, and is positioned to potentially deliver the first therapy specifically designed to prevent brain swelling in stroke, a condition responsible for significant morbidity and mortality.

Small-molecule inhibitors targeting aquaporin water channels, specifically Aquaporin-4 (AQP4), to control cerebral edema.

AER-271 is first-in-class with no direct competitors targeting AQP4. Indirect competition includes supportive care (osmotic agents), invasive surgery (decompressive craniectomy), and general neuroprotective agents in development. The novel mechanism provides a significant differentiation if clinically proven.